Trial · NCT02627430
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
NCT02627430, Phase 1, Withdrawn, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer. Trials, record NCT02627430. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02627430
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
- NCT number
- NCT02627430
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, Fallopian Tube Serous Neoplasm, HER2/Neu Negative, Ovarian Serous Adenocarcinoma, Ovarian Serous Tumor, Primary Peritoneal Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Triple-Negative Breast Carcinoma
- Interventions
- Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- First posted
- 2015-12-11
- Last updated
- 2016-07-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MTD based on the dose-limiting toxicity based on the National Cancer Institute (NCI) CTCAE v. 4.0 | 35 days | DLT defined as non-hematologic and hematologic toxicities experienced during course 0 and the first course (i.e. first 4 weeks) of treatment. |
| Secondary | Incidence of adverse events as assessed by NCI CTCAE v. 4.0 | 30 days post-treatment | |
| Secondary | Pharmacokinetic (PK) parameters of talazoparib and HSP90 inhibitor AT13387 | Baseline, at 1, 2, 4 and 8 hours of day 1 (course 0), baseline of days 1, 8, and 15 of course 1, and at 1, 2, 4, and 8 hours post-dosing on day 8 and 15 of course 1 | Pearson correlation coefficients, presented with 95% confidence intervals, will be used to investigate the association of the percent change heat shock protein 90 and poly(adenosine diphosphate-ribose) polymerase 1 activities with PK parameters, including maximum concentration observed and area under the curve. |
| Other | Change in BRCA1 foci expression in tumor tissue via IHC | Baseline to day 15 of course 1 | Paired t-tests will be used to compare BRCA1 foci formation following BMN673/AT13387. |
| Other | Change in BRCA1 foci expression in tumor tissue via immunohistochmestry (IHC) | Baseline to day 7 of course 0 | Paired t-tests will be used to compare BRCA1 foci formation following BMN673. |
| Other | Change in heat shock protein 70 (HSPT70) expression | Day 7 (course 0) to day 15 (course 1) | Changes in parameters of HSP70 activities that occur post-treatment will be summarized using descriptive statistics. |
| Other | Change in RAD51 foci expression in tumor tissue via IHC | Baseline to day 15 of course 1 | Paired t-tests will be used to compare RAD51 foci formation following BMN673/AT13387. |
| Other | Change in RAD51 recombinase (RAD51) foci expression in tumor tissue via IHC | Baseline to day 7 of course 0 | Paired t-tests will be used to compare RAD51 foci formation following BMN673. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P30CA006516 | Dana-Farber/Harvard Cancer Center | EBERT, BENJAMIN LEVINE | DANA-FARBER CANCER INST | NATIONAL CANCER INSTITUTE | 1985 to 2025 | NIH RePORTER |
| UM1CA186709 | Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) | SHAPIRO, GEOFFREY I.; FLAHERTY, KEITH T; KUFE, DONALD W. | DANA-FARBER CANCER INST | NATIONAL CANCER INSTITUTE | 2014 to 2025 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02627430
GET https://conductscience.org/api/trials/v1/NCT02627430/registered